MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.460
+0.300
+9.49%
After Hours: 3.290 -0.17 -4.91% 19:30 05/14 EDT
OPEN
3.250
PREV CLOSE
3.160
HIGH
3.620
LOW
3.240
VOLUME
433.18K
TURNOVER
--
52 WEEK HIGH
5.11
52 WEEK LOW
1.780
MARKET CAP
166.71M
P/E (TTM)
-2.0886
1D
5D
1M
3M
1Y
5Y
BRIEF-Synlogic Reports Q1 Loss Per Share Of $0.36
reuters.com · 1d ago
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 1d ago
Synlogic EPS beats by $0.03
Synlogic (SYBX): Q1 GAAP EPS of -$0.36 beats by $0.03.As of March 31, 2021, Synlogic had cash, cash equivalents and short-term investments of $94.4 million. Press Release
Seekingalpha · 1d ago
Synlogic Q1 EPS $(0.36) Beats $(0.39) Estimate
Synlogic (NASDAQ:SYBX) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 21.74 percent increase over losses of $(0.46) per share from the same
Benzinga · 1d ago
Synlogic Reports First Quarter Financial Results and Provides Business Update
, May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an upda...
PR Newswire - PRF · 1d ago
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 1d ago
The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026
, /PRNewswire/ -- Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders or disabilities; it is a heritable and a polygenic disorder. Autism spectrum disorder is lifelong and typically emerges during early childhood. Children sh...
PR Newswire - PRF · 2d ago
This is Why a Healthy Gut is Crucial for Your Wellbeing
A healthy gut can help improve everything from your emotional state of mind to your immune system. In fact, according to Euromonitor International, “about one-quarter of consumers globally suffer from lower digestive health issues. In half ...
Baystreet.ca · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYBX. Analyze the recent business situations of Synlogic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYBX stock price target is 10.71 with a high estimate of 15.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 25.38M
% Owned: 52.68%
Shares Outstanding: 48.18M
TypeInstitutionsShares
Increased
15
601.72K
New
14
3.21M
Decreased
10
365.43K
Sold Out
4
26.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Independent Director
Peter Barrett
President/Chief Executive Officer/Director
Aoife Brennan
Chief Financial Officer
Gregg Beloff
Finance Director/Senior Vice President
Daniel Rosan
Vice President
Jamie Austin
Other
David Hava
Other
Caroline Kurtz
Other
Richard Riese
Other
Michael Slater
Director
Michael Heffernan
Director
Lisa Kelly-Croswell
Independent Director
Michael Burgess
Independent Director
Patricia Hurter
Independent Director
Chau Khuong
Independent Director
Nick Leschly
Independent Director
Edward Mathers
Independent Director
Richard Shea
No Data
  • All
  • Financials
  • Insiders
More
About SYBX
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.